BioMarin bulks up bone unit with $275M Alesta buyout to challenge AstraZeneca

BioMarin Pharmaceutical has agreed to buy Alesta Therapeutics for $275 million upfront, positioning the biopharma to challenge AstraZeneca in the rare bone disease market.